The World Health Organization (WHO) Ebola emergency committee that met today to review the outbreak situation in the Democratic Republic of the Congo (DRC) recommended continuing the public health emergency of international concern under International Health Regulations.
A team of Spanish scientists reports that after they implemented an antimicrobial stewardship program (ASP) focused on antifungal use at their university hospital in Seville, use of antifungal drugs dropped 38%, according to their findings published yesterday in the Journal of Infection.
The Agency for Healthcare Research and Quality (AHRQ) has released a new toolkit to improve antibiotic use in acute care hospitals.
The proportion of candidemia in patients with injection drug use more than doubled.
Health officials in New York's Rockland County today declared the end of a 2018-2019 measles outbreak that sickened 312 people, a development that decreases the chance of the United States losing its measles elimination status on Oct 2.
The US Centers for Disease Control and Prevention (CDC) announced yesterday that the Pan American Health Organization (PAHO)/World Health Organization (WHO) have designated the CDC's Center for Global Health as a PAHO/WHO Collaborating Center for Biosafety and Biosecurity.
A study conducted in Dutch hospitals has found that an isolation strategy of contact precautions in a multiple-bed hospital room was non-inferior to a strategy of contact precautions in a single-bed room for preventing the spread of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, Dutch researchers reported in The Lancet Infectious Diseases.
Taco Bell announced yesterday that it aims to reduce the amount of medically important antibiotics used in its US and Canadian beef supply chains by 25% by 2025.
Could climate change have played a role in the emergence of the multidrug-resistant fungus Candida auris?
The US Food and Drug Administration (FDA) today announced the approval of Recarbrio, a new three-drug antibacterial product developed by Merck, for treating patients with complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs) caused by gram-negative pathogens.
